These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 7914540)

  • 41. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
    Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serotonin 5-HT2 receptor, dopamine D2 receptor, and alpha 1 adrenoceptor antagonists. Conformationally flexible analogues of the atypical antipsychotic sertindole.
    Andersen K; Liljefors T; Hyttel J; Perregaard J
    J Med Chem; 1996 Sep; 39(19):3723-38. PubMed ID: 8809161
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.
    Langlois X; Megens A; Lavreysen H; Atack J; Cik M; te Riele P; Peeters L; Wouters R; Vermeire J; Hendrickx H; Macdonald G; De Bruyn M
    J Pharmacol Exp Ther; 2012 Jul; 342(1):91-105. PubMed ID: 22490380
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis and binding affinity of novel 3-aminoethyl-1-tetralones, potential atypical antipsychotics.
    Alvarado M; Coelho A; Masaguer CF; Raviña E; Brea J; Padín JF; Loza MI
    Bioorg Med Chem Lett; 2005 Jun; 15(12):3063-6. PubMed ID: 15878662
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents.
    Howard HR; Lowe JA; Seeger TF; Seymour PA; Zorn SH; Maloney PR; Ewing FE; Newman ME; Schmidt AW; Furman JS; Robinson GL; Jackson E; Johnson C; Morrone J
    J Med Chem; 1996 Jan; 39(1):143-8. PubMed ID: 8568801
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel benzothiazolin-2-one and benzoxazin-3-one arylpiperazine derivatives with mixed 5HT1A/D2 affinity as potential atypical antipsychotics.
    Taverne T; Diouf O; Depreux P; Poupaert JH; Lesieur D; Guardiola-Lemaître B; Renard P; Rettori MC; Caignard DH; Pfeiffer B
    J Med Chem; 1998 Jun; 41(12):2010-8. PubMed ID: 9622542
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of streptozotocin-induced diabetes on dopamine2, serotonin1A and serotonin2A receptors in the rat brain.
    Sumiyoshi T; Ichikawa J; Meltzer HY
    Neuropsychopharmacology; 1997 Mar; 16(3):183-90. PubMed ID: 9138434
    [TBL] [Abstract][Full Text] [Related]  

  • 49. "Hit-and-run" actions at dopamine receptors, part 1: Mechanism of action of atypical antipsychotics.
    Stahl SM
    J Clin Psychiatry; 2001 Sep; 62(9):670-1. PubMed ID: 11681760
    [TBL] [Abstract][Full Text] [Related]  

  • 50. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and antidopaminergic activity of some 3-(aminomethyl)tetralones as analogues of butyrophenone.
    Cortizo L; Santana L; Ravina E; Orallo F; Fontenla JA; Castro E; Calleja JM; de Ceballos ML
    J Med Chem; 1991 Jul; 34(7):2242-7. PubMed ID: 1676759
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
    Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dopamine receptor binding of 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)- 4-oxobutyl]-1,2,3,6-tetrahydropyridine (HPTP), an intermediate metabolite of haloperidol.
    Brand L; Oliver DW; van der Schyf CJ; Pond SM; Castagnoli N
    Life Sci; 1996; 59(10):815-20. PubMed ID: 8761315
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of ritanserin on haloperidol-induced dopamine (D2) receptor up-regulation in the rat.
    Szczepanik AM; Wilmot CA
    Neurosci Lett; 1997 Aug; 231(2):91-4. PubMed ID: 9291148
    [TBL] [Abstract][Full Text] [Related]  

  • 55. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
    Millan MJ; Brocco M; Rivet JM; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion JL; Dekeyne A
    J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol.
    Sumiyoshi T; Kido H; Sakamoto H; Urasaki K; Suzuki K; Yamaguchi N; Mori H; Shiba K; Yokogawa K
    Pharmacol Biochem Behav; 1994 Mar; 47(3):553-7. PubMed ID: 7516078
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of atypical antipsychotic agents on social behavior in rodents.
    Corbett R; Hartman H; Kerman LL; Woods AT; Strupczewski JT; Helsley GC; Conway PC; Dunn RW
    Pharmacol Biochem Behav; 1993 May; 45(1):9-17. PubMed ID: 7685916
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis and preliminary pharmacological investigations of 1-(1,2-dihydro-2-acenaphthylenyl)piperazine derivatives as potential atypical antipsychotic agents in mice.
    Srinivas P; Subramanian AR; Brust P; Raghavan SA; Rangisetty JB; Gupta CN; Sridhar N; Veeranjaneyulu A; Parimoo P
    Farmaco; 1999 Aug; 54(8):567-72. PubMed ID: 10510854
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs.
    Meltzer HY; Matsubara S; Lee JC
    Psychopharmacol Bull; 1989; 25(3):390-2. PubMed ID: 2576319
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841.
    Krisch I; Bole-Vunduk B; Pepelnak M; Lavric B; Ocvirk A; Budihna MV; Sket D
    J Pharmacol Exp Ther; 1994 Oct; 271(1):343-52. PubMed ID: 7965734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.